Vertex, Mitsubishi HCV deal

Mitsubishi Pharma (Tokyo, Japan) received exclusive development and marketing rights to VRTX's VX-950 oral protease inhibitor to treat HCV infection in Japan and certain Far East countries. VRTX expec...